Date: 2015-05-20
Type of information: Licensing agreement
Compound: Pichia pastoris expression strains for the commercial production of recombinant allergens
Company: Biomay (Austria) VTU Technology (Austria)
Therapeutic area: Technology - Services - Allergic diseases
Type agreement: licensing
Action mechanism:
Disease: allergic diseases
Details: * On May 20, 2015, VTU Technology and Biomay, two leading Austrian biotech companies, announced that they have entered into a licensing agreement for the production of recombinant allergens. VTU Technology, currently offering a very broad and comprehensive Pichia pastoris expression platform, grants Biomay access to VTU´s Pichia pastoris protein expression technology. Biomay, a global leader in allergy immunotherapy, will apply industrial Pichia expression strains generated by VTU for the commercial production of recombinant allergens. Biomay’s lead product is BM32 – a recombinant-based therapeutic vaccine against grass pollen allergy, which is the most advanced candidate developed from Biomay´s proprietary peptide-carrier technology. BM32 has achieved promising results in a recently concluded Phase IIb placebo-controlled, multinational trial. Additionally, Biomay operates as a Contract Manufacturing Organisation (CMO), offering services for GMP-conform microbial-derived recombinant proteins and plasmid DNA.
Financial terms: Under the terms of the agreement, VTU Technology will receive royalties based on Biomay´s worldwide sales of the recombinant allergens.
Latest news:
